A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.
A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.
The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.
Inclusion criteria:
Exclusion criteria:
Aichi, Toyoake, 470-1192, Japan
Chiba, Chiba, 263-0043, Japan
Kanagawa, Fujisawa, 251-0038, Japan
Kyoto, Kyoto, 606-0851, Japan
Nara, Kashihara, 634-8522, Japan
Okayama, Kurashiki, 710-0813, Japan
Tokyo, Kodaira, 187-8551, Japan
Tokyo, Mitaka, 181-0013, Japan
Tokyo, Shinagawa, 142-0054, Japan